As per the ESSENCE trial, the dose that benefits the liver is 2.4 mg weekly with 1.7 mg weekly as a fallback if 2.4 mg is not tolerated
And retatrutide, the triple agonist, shows the highest rates
If you have been on 10 units (0.5 mg from a 5 mg/mL vial) for four weeks and feel no difference in appetite, discuss with your provider whether escalation is appropriate
As observed in the STEP trials, treatment discontinuations due to AEs occurred in 2.4%7.0% of participants receiving semaglutide, compared with 1.0%4.6% of those receiving placebo [13, 38,39,40,41,42,43,44,45,46]
A real evaluation, brand-name FDA-approved options, and ongoing follow-up that goes beyond a prescription
Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study